Drug Trial Radar · NCT06044337
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
306
Planned (sponsor's estimate)
Start
Oct 3, 2023
Primary completion
Jun 26, 2029
Study completion Dec 11, 2029
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue. The study will enroll only those participants who have completed treatment with litifilimab in the parent study, 230LE301. The main objective of the study is to learn more about the long-term safety of litifilimab. The main question researchers want to answer is: * How many participants have adverse events and serious adverse events after taking litifilimab? Adverse events are health problems that may or may not be caused by the study drug. Researchers will also learn more about the effect of litifilimab on CLE. They will do this by measuring the symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI). Researchers will look at how litifilimab and CLE affect the quality of life of participants using a group of questionnaires. They will also look at how litifilimab affects laboratory tests and how participants' immune systems respond to litifilimab. The study will be done as follows: * The last visit of parent study 230LE301 will be the first visit of study 230LE305. * All participants will receive litifilimab as an injection under the skin once every 4 weeks. Both researchers and participants will know the dose and identity of the study drug. * Globally, the treatment period will last up to 208 weeks, or 4 years. Participants will have up to 53 study visits during this time.
Conditions
- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus
Interventions
BIIB059 (litifilimab)Drug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 232 weeks
Locations
104 sites in 25 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - (UAB)
Birmingham, Alabama
Arizona Arthritis & Rheumatology Research, PLLC
Phoenix, Arizona
Dermatology Research Associates
Los Angeles, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
David Fivenson, MD, Dermatology, PLLC
Ann Arbor, Michigan
Revival Research Institute, LLC
Troy, Michigan
Saint Louis University
St Louis, Missouri
Thurston Arthritis Research Center
Chapel Hill, North Carolina
Duke Dermatology South Durham
Durham, North Carolina
University of Cincinnati Health Physicians Office Dermatology
Cincinnati, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Precision Comprehensive Clinical Research Solutions
Grapevine, Texas
APRILLUS Asistencia e Investigacion
Buenos Aires, Argentina
Instituto CAICI
Rosario, Santa Fe Province, Argentina
Investigaciones Clinicas Tucuman
San Miguel de Tucumán, Tucumán Province, Argentina
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, Tucumán Province, Argentina
IDERJ - Instituto de Dermatologia e Estética do Brasil Ltda
Rio de Janeiro, Brazil
Clínica SER da Bahia
Salvador, Estado de Bahia, Brazil
L2IP - Instituto de Pesquisas Clínicas Ltda.
Brasília, Federal District, Brazil
IPC MT Instituto de Pesquisas Clinicas do Mato Grosso
Santo Ângelo, Mato Grosso, Brazil
CMiP - Centro Mineiro de Pesquisa
Juiz de Fora, Minas Gerais, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Nucleo de Pesquisa Clinica do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
LMK Serviços Médicos S/S Ltda
Porto Alegre, Rio Grande do Sul, Brazil
CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos
São Paulo, São Paulo, Brazil
DCC 'Alexandrovska', EOOD
Sofia, Bulgaria
DCC Focus 5 - MEOH OOD
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD
Sofia, Sofia City Province, Bulgaria
Laser Rejuvenation Clinics, Inc.
Calgary, Alberta, Canada
DIEX Recherche Sherbrooke Inc.
Sherbrooke, Quebec, Canada
Centro Medico SkinMed
Las Condes, Chile
CIEC - Centro Internacional de Estudios Clínicos
Santiago, Chile
Clinical Research Chile SpA
Valdivia, Chile
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Dongguan People's Hospital
Dongguan, Guangdongsheng, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdongsheng, China
The second Xiangya Hospital of Central South University
Changsha, Húnánsheng, China
Hospital for Skin Diseases, Chinese Academy of Medical Sciences
Nanjing, Jiangsu, China
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.